Ramucirumab: the long and winding road toward being an option for mCRC treatment

References

• Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386–1422.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.
   PubMed Web of Science ®Google Scholar
• Youssoufian H, Hicklin DJ, Rowinsky EK. Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy. Clin Cancer Res. 2007;13:5544–5549.
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013–2019.
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539–1544.
   PubMed Web of Science ®Google Scholar
• Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14:29–37.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30:3499–3506.
   PubMed Web of Science ®Google Scholar
• Folprecht G, Pericay C, Saunders MP, et al. Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study. Ann Oncol. 2016;27:1273–1279.
   PubMed Web of Science ®Google Scholar
• Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303–312.
   PubMed Web of Science ®Google Scholar
• Ferrera N. The biology of VEGF and its receptors and the mechanisms of anti-tumour activity. Nat Med. 2003;9:669–676.
   PubMedGoogle Scholar
• Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (imc-1121b), a fully human immunoglobulin G1monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol. 2010;28:780–787.
   PubMed Web of Science ®Google Scholar
• Chiorean EG, Hurwitz HI, Cohen RB, et al. Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors. Ann Oncol. 2015;26:1230–1237.
   PubMed Web of Science ®Google Scholar
• Yoshino T, Yamazaki K, Gotoh M, et al. Safety and pharmacokinetics of second-line Ramucirumab plus FOLFIRI in Japanese patients with metastatic colorectal carcinoma. Anticancer Res. 2015;35:4003–4007.
   PubMed Web of Science ®Google Scholar
• Nokihara H, Yamamoto N, Yamada Y, et al. A phase 1 study of ramucirumab in Japanese patients with advanced solid tumors. Jpn J Clin Oncol. 2017;47:298–305.
   PubMed Web of Science ®Google Scholar
• Shitara K, Kadowaki S, Nishina T, et al. Safety, pharmacokinetic, and clinical activity profiles of ramucirumab in combination with three platinum/fluoropyrimidine doublets in Japanese patients with chemotherapy-naïve metastatic gastric/gastroesophageal junction cancer. Gastric Cancer. 2018 Jan;21(1):106–113.
   PubMed Web of Science ®Google Scholar
• Cao J, Ji D, Chen Z, et al. Phase I dose‐escalation study of ramucirumab in Chinese patients with advanced solid tumors. Oncologist. 2017;22:638–e56.
   PubMed Web of Science ®Google Scholar
• Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224–1235.
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31–39.
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Rivera F, Maurel J, et al. An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer. Oncologist. 2014;19:350–351.
   PubMed Web of Science ®Google Scholar
• Moore M, Gill S, Asmis T, et al. Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy. Ann Oncol Off J Eur Soc Med Oncol. 2016;27:2216–2224.
   PubMed Web of Science ®Google Scholar
• Tabernero J, Yoshino T, Cohn AL, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin. Lancet Oncol. 2015;16:499–508.
   PubMed Web of Science ®Google Scholar
• Boku N, Yamamoto S. Selection of second-line anti-angiogenic agents after failure of bevacizumab-containing first-line chemotherapy in metastatic colorectal cancer. Clin Colorectal Cancer. [Internet]. 2018;17:251–254. [cited 2018 Dec 19]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30149985
   PubMed Web of Science ®Google Scholar
• Beştaş R, Kaplan MA, Işikdoğan A. The correlation between serum VEGF levels and known prognostic risk factors in colorectal carcinoma. Hepatogastroenterology. [Internet]. 61:267–271. [cited 2018 Dec 19]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24901122
   PubMedGoogle Scholar
• Kwon KA, Kim SH, Oh SY, et al. Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer. BMC Cancer. [Internet]. 2010;10:203. [cited 2018 Dec 19]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20465852
   PubMed Web of Science ®Google Scholar
• Divella R, Daniele A, DE LR, et al. Circulating levels of VEGF and CXCL1 are predictive of metastatic organotropismin in patients with colorectal cancer. Anticancer Res. [Internet]. 2017;37:4867–4871. [cited 2018 Dec 19]. Available from: http://ar.iiarjournals.org/content/37/9/4867.abstract
   PubMed Web of Science ®Google Scholar
• Marisi G, Scarpi E, Passardi A, et al. Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab. Sci Rep. 2017;7:1293.
   Web of Science ®Google Scholar
• Tebbutt NC, Wilson K, Gebski VJ, et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian gastrointestinal trials group randomized phase III MAX study. J Clin Oncol. 2010;28:3191–3198.
   PubMed Web of Science ®Google Scholar
• Weickhardt AJ, Williams DS, Lee CK, et al. Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer. Br J Cancer. 2015;113:37–35.
   Web of Science ®Google Scholar
• Nixon AB, Sibley A, Hatch AJ, et al. Blood-based biomarkers in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab (Cetux), or Bev plus Cetux: results from CALGB 80405 (Alliance). J Clin Oncol. [Internet]. 2016;34:3597. [cited 2018 Dec 19]. Available from: http://ascopubs.org/doi/10.1200/JCO.2016.34.15_suppl.3597
   PubMedGoogle Scholar
• Tabernero J, Hozak RR, Yoshino T, et al. Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study. Ann Oncol. 2018;29:602–609.
   PubMed Web of Science ®Google Scholar
• Willett CG, Boucher Y, Duda DG, et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol. 2005;23:8136–8139.
   Web of Science ®Google Scholar
• Deprimo SE, Bello C. Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib. Ann Oncol. 2007;18:x11–x19.
   PubMed Web of Science ®Google Scholar
• Shaked Y, Bertolini F, Man S, et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell. 2005;7:101–111.
   PubMed Web of Science ®Google Scholar
• Gerger A, El-Khoueiry A, Zhang W, et al. Pharmacogenetic angiogenesis profiling for first-line bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res. 2011;17:5783–5792.
   PubMed Web of Science ®Google Scholar
• Schultheis AM, Lurje G, Rhodes KE, et al. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res. 2008;14:7554–7563.
   PubMed Web of Science ®Google Scholar
• Lambrechts D, Delmar P, Miles DW, et al. Single nucleotide polymorphism analysis and outcome in advanced-stage cancer patients treated with bevacizumab. Eur J Cancer. 2011;47:S173.
   Web of Science ®Google Scholar
• Lambrechts D, Claes B, Delmar P, et al. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol. 2012;13:724–733.
   PubMedGoogle Scholar
• Loupakis F, Ruzzo A, Salvatore L, et al. Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer. 2011;11:247.
   PubMed Web of Science ®Google Scholar
• Loupakis F, Cremolini C, Dongyun Y, et al. Prospective validation of candidate snps of vegf/vegfr pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. PLoS One. 2013;7:e66774.
   PubMed Web of Science ®Google Scholar
• Bramswig KH, Poettler M, Unseld M, et al. Soluble carcinoembryonic antigen activates endothelial cells and tumor angiogenesis. Cancer Res. 2013;73:6584–6596.
   PubMed Web of Science ®Google Scholar
• Thirunavukarasu P, Sukumar S, Sathaiah M, et al. C-stage in colon cancer: implications of carcinoembryonic antigen biomarker in staging, prognosis, and management. J Natl Cancer Inst. 2011; 103:689–697.
   PubMedGoogle Scholar
• Prager GW, Braemswig KH, Martel A, et al. Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer. Cancer Sci. 2014; 105:996–1001.
   PubMed Web of Science ®Google Scholar
• Holch JW, Ricard I, Stintzing S, et al. Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). Eur J Cancer. [Internet]. 2019;106:115–125. [cited 2018 Dec 19]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30496943
   PubMed Web of Science ®Google Scholar
• Kishi Y, Kopetz S, Chun YS, et al. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol. 2009;16:614–622.
   Web of Science ®Google Scholar
• Tecchio C, Cassatella MA. Neutrophil-derived cytokines involved in physiological and pathological angiogenesis. Chem Immunol Allergy. 2013;99:123–137.
   PubMedGoogle Scholar
• Tohme S, Yazdani HO, Al-Khafaji AB, et al. Neutrophil extracellular traps promote the development and progression of liver metastases after surgical stress. Cancer Res. 2016;76:1367–1380.
   PubMed Web of Science ®Google Scholar
• Watt DG, Martin JC, Park JH, et al. Neutrophil count is the most important prognostic component of the differential white cell count in patients undergoing elective surgery for colorectal cancer. Am J Surg. 2015;210:24–30.
   PubMed Web of Science ®Google Scholar
• Grothey A, Yoshino T, Bodoky G, et al. Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data se. ESMO Open. 2018;3:e000347.
   PubMed Web of Science ®Google Scholar
• Arnold D, Lueza B, Douillard JY, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28:1713–1729.
   Google Scholar
• Goel G. Molecular characterization and biomarker identification in colorectal cancer: toward realization of the precision medicine dream. Cancer Manag Res. [Internet]. 2018;10:5895–5908. [cited 2018 Dec 19]. Available from: https://www.dovepress.com/molecular-characterization-and-biomarker-identification-in-colorectal–peer-reviewed-article-CMAR
   PubMed Web of Science ®Google Scholar
• Richman SD, Seymour MT, Chambers P, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol. 2009;27:5931–5937.
   Google Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757–1765.
   PubMed Web of Science ®Google Scholar
• Andreyev HJN, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the “RASCAL II” study. Br J Cancer. 2001;85:692–696.
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Yi J, Ince W, et al. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist. [Internet]. 2009;14:22–28. Available from: http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theoncologist.2008-0213
   PubMed Web of Science ®Google Scholar
• Lambrechts D, Thienpont B, Thuillier V, et al. Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting. Br J Cancer. 2015;113:1027–1034.
   Google Scholar
• Yoshino T, Portnoy DC, Obermannová R, et al. Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE, a global phase 3 study. Ann Oncol. [Internet]. 2018;1–8. Available from: https://academic.oup.com/annonc/advance-article/doi/10.1093/annonc/mdy461/5136414
   Google Scholar
• Sayagués JM, Del Carmen S, Abad MDM, et al. Combined assessment of the TNM stage and BRAF mutational status at diagnosis in sporadic colorectal cancer patients. Oncotarget. 2018;9:24081–24096.
   Google Scholar
• Wirapati P, Pomella V, Vandenbosch B, et al. Velour trial biomarkers update: impact of RAS, BRAF, and sidedness on aflibercept activity. J Clin Oncol. 2017;35:no. 15_suppl.
   Web of Science ®Google Scholar
• Ince WL, Jubb AM, Holden SN, et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst. 2005;97:981–989.
   PubMedGoogle Scholar
• Tada Y, Togashi Y, Kotani D, et al. Targeting VEGFR2 with ramucirumab strongly impacts effector/activated regulatory T cells and CD8+ T cells in the tumor microenvironment. J Immunother Cancer. 2018;6:1–14.
   PubMed Web of Science ®Google Scholar
• Masi G, Salvatore L, Boni L, et al. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. Ann Oncol. 2015;26:724–730.
   PubMed Web of Science ®Google Scholar
• Tabernero J, Van Cutsem E, Lakomý R, et al. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer. 2014;50:320–331.
   PubMed Web of Science ®Google Scholar
• Arnold D, Fuchs CS, Tabernero J, et al. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. Ann Oncol. 2017;28:2932–2942.
   PubMed Web of Science ®Google Scholar
• Wang J, Wang Z, Zhao Y. Incidence and risk of hypertension with ramucirumab in cancer patients: a meta-analysis of published studies. Clin Drug Investig. 2015;35:221–228.
   PubMed Web of Science ®Google Scholar
• Keefe D, Bowen J, Gibson R, et al. Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review. Oncologist. 2011;16:432–444.
   PubMed Web of Science ®Google Scholar
• Nazer B, Humphreys BD, Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation. 2011;124:1687–1691.
   PubMed Web of Science ®Google Scholar
• Shirakawa T, Nakano M, Nio K, et al. Retrospective analysis of cardiovascular diseases related to chemotherapies for advanced solid tumor patients. Anticancer Drugs. 2016;27:891–898.
   PubMed Web of Science ®Google Scholar
• McIntyre K. An oncology nurses’ guide to new targeted agents for metastatic colorectal cancer. Clin J Oncol Nurs. 2015;19:571–579.
   PubMed Web of Science ®Google Scholar
• Maitland ML, Bakris GL, Black HR, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010;102:596–604.
   PubMed Web of Science ®Google Scholar
• Arora N, Gupta A, Singh PP. Biological agents in gastrointestinal cancers: adverse effects and their management. J Gastrointest Oncol. 2017;8:485–498.
   PubMed Web of Science ®Google Scholar
• Peng L, Zhao Q, Ye X, et al. Incidence and risk of proteinuria with aflibercept in cancer patients: a meta-analysis. PLoS One. 2014;9:e111839.
   Google Scholar
• Wu S, Kim C, Baer L, et al. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol. 2010;21:1381–1389.
   Web of Science ®Google Scholar
• Gurevich F, Perazella MA. Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med. 2009;122:322–328.
   PubMed Web of Science ®Google Scholar
• Larmour KE, Maxwell AP, Courtney AE. Improving early detection of chronic kidney disease. Practitioner. 2015;259:19–23, 2–3.
   Google Scholar
• Lewis G, Maxwell AP. Timely diagnosis and treatment essential in glomerulonephritis. Practitioner. 2015;259: 13–17, 2.
   PubMedGoogle Scholar
• Ferrara N. VEGF: an update on biological and therapeutic aspects. Curr Opin Biotechnol. 2000;11:617–624.
   PubMed Web of Science ®Google Scholar
• Gordon CR, Rojavin Y, Patel M, et al. A review on bevacizumab and surgical wound healing. Ann Plast Surg. 2009;62:707–709.
   PubMed Web of Science ®Google Scholar
• Kamba T, Tam BYY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol. 2006;290:H560–76.
   PubMed Web of Science ®Google Scholar
• Roodhart JM, Langenberg MH, Witteveen E, et al. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol. 2008;3:132–143.
   PubMedGoogle Scholar
• Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96:1788–1795.
   PubMed Web of Science ®Google Scholar
• Kakar P, Lip GYH. Towards understanding the aetiology and pathophysiology of human hypertension: where are we now? J Hum Hypertens. 2006;20:833–836.
   PubMed Web of Science ®Google Scholar
• Vlachostergios PJ, Lee A, Thomas C, et al. A critical review on ramucirumab in the treatment of advanced urothelial cancer. Futur Oncol. 2018;14:1049–1061.
   PubMed Web of Science ®Google Scholar
• Aprile G, Ferrari L, Cremolini C, et al. Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies. Expert Rev Clin Pharmacol. 2016;9:877–885.
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Li X, Treps L, et al. RAISEing VEGF-D’s importance as predictive biomarker for ramucirumab in metastatic colorectal cancer patients. Ann Oncol. 2018;29:527–529.
   PubMed Web of Science ®Google Scholar
• Satoshi Y, Kentaro Y, Hiroya T, et al. The nationwide screening project on plasma angiogenesis-related mediators for treatment selection of optimal antiangiogenic inhibitors in metastatic colorectal cancer: GI-SCREEN CRC-Ukit. J Clin Oncol. 2018;36:no. 4_suppl.
   Web of Science ®Google Scholar
• Fuch CS, Shitara K, Di Bartolomeo M, et al. RAINFALL: a randomized, double-blind, placebo-controlled phase III study of cisplatin (Cis) plus capecitabine (cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastoesophageal junction (G-GEJ) ade. J Clin Oncol. 2018;36:no. 4_suppl.
   Web of Science ®Google Scholar
• Sama AR, Denlinger CS, Vogel A, et al. Gemcitabine and cisplatin plus ramucirumab or merestinib or placebo in first-line treatment for advanced or metastatic biliary tract cancer: a double-blind, randomized phase II trial. J Clin Oncol. [Internet]. 2017;35: TPS509. [cited 2018 Dec 20]. Available from: http://ascopubs.org/doi/10.1200/JCO.2017.35.4_suppl.TPS509
   Web of Science ®Google Scholar
• RAMucirumab in combination With TAS102 vs. TAS102 alone in chemotherapy refractory metastatic colorectal cancer patients (RAMTAS) [Internet]. [cited 2018 May]. Available from: https://clinicaltrials.gov/ct2/show/NCT03520946
   Google Scholar
• Hochster HS, Catalano PJ, O’Dwyer PJ, et al. Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: result of E7208. (abstract). J Clin Oncol. 2018;36:no. 15_suppl.
   Google Scholar
• Seeber A, Gunsilius E, Gastl G, et al. Anti-angiogenics: their value in colorectal cancer therapy. Oncol Res Treat. 2018;41:188–193.
   PubMed Web of Science ®Google Scholar
• Apatinib versus bevacizumab in second-line therapy for colorectal cancer (ABST-C) NCT03271255.
   Google Scholar